Psychedelic drug contender stocks drop after FDA rejects MDMA treatment




Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.



  • Related Posts

    3 ways to make sure the ‘great wealth transfer’ enriches your family
    • August 16, 2025

    From ‘affluenza’ to abundance: How to teach heirs to value their privilege — and your money

    Continue reading
    Opendoor bulls are getting what they want, and the stock is surging again
    • August 15, 2025

    CEO Carrie Wheeler has stepped down to the delight of institutional investors.

    Continue reading

    Random News

    West Virginia sending National Guard troops to D.C. at Trump’s request

    • By gonews
    • August 16, 2025
    • 1 views

    Judge says FTC investigation into Media Matters ‘should alarm all Americans’

    • By gonews
    • August 16, 2025
    • 1 views
    Judge says FTC investigation into Media Matters ‘should alarm all Americans’

    2025 New England Patriots Season Preview; Bracket Banter Podcast

    • By gonews
    • August 16, 2025
    • 2 views
    2025 New England Patriots Season Preview; Bracket Banter Podcast

    تظاهرات في نيوزيلندا للمطالبة بوقف الإبادة الجماعية بغزة

    • By gonews
    • August 16, 2025
    • 1 views
    تظاهرات في نيوزيلندا للمطالبة بوقف الإبادة الجماعية بغزة